Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (130)

2024

  1. Dynamic assessment of CHA2DS2-VASc and HAS-BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients

    Revista Espanola de Cardiologia, Vol. 77, Núm. 10, pp. 835-842

  2. Predicting Bleeding in Cancer-Associated Venous Thromboembolism: Another Milestone Achieved

    Thrombosis and Haemostasis

2023

  1. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment

    American Journal of Cardiology, Vol. 203, pp. 122-127

  2. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making

    American Heart Journal, Vol. 258, pp. 1-16

  3. Impact of particulate matter on the incidence of atrial fibrillation and the risk of adverse clinical outcomes: A review

    Science of the Total Environment, Vol. 880

  4. Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban

    Journal of comparative effectiveness research, Vol. 12, Núm. 3, pp. e220049

  5. Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

    Biomedicine and Pharmacotherapy, Vol. 158

  6. Reducing bleeding risk in patients on oral anticoagulation therapy

    Expert Review of Cardiovascular Therapy, Vol. 21, Núm. 12, pp. 923-936

  7. Reticulated Platelets: A Promising Prognosis Marker in Cardiovascular Diseases

    Thrombosis and Haemostasis, Vol. 124, Núm. 4, pp. 320-323

  8. The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

    Journal of General Internal Medicine, Vol. 38, Núm. 2, pp. 315-323

2022

  1. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper

    Thrombosis and Haemostasis, Vol. 122, Núm. 10, pp. 1625-1652

  2. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society

    Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, Vol. 24, Núm. 11, pp. 1844-1871

  3. Current trends on antithrombotic therapy

    REC: CardioClinics

  4. Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?

    Revista Espanola de Cardiologia, Vol. 75, Núm. 9, pp. 705-706

  5. Editorial: New horizons in the management of patients with atrial fibrillation: Interactions with the gastrointestinal system

    Frontiers in Cardiovascular Medicine

  6. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 1, pp. 282-289

  7. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study

    Cardiology Journal, Vol. 29, Núm. 4, pp. 601-609

  8. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry

    European heart journal. Cardiovascular pharmacotherapy, Vol. 9, Núm. 1, pp. 38-46

  9. Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients

    European Journal of Internal Medicine

  10. Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists

    Journal of Personalized Medicine, Vol. 12, Núm. 3